Design of a Novel Peptide Inhibitor of HIV Fusion that Disrupts the Internal Trimeric Coiled-coil of gp41
Description of Invention:
This invention provides a peptide derived from the sequence of the N-terminal helix (residues 546-581) of the gp41 ectodomain of HIV-1. The peptide, called N36Mut(e,g), contains nine substitutions and disrupts interactions with the C-terminal region of the gp41 ectodomain. N36Mut(e,g) inhibits HIV-envelope mediated cell fusion about 50-fold more effectively than the native sequence (residues 546-581 of HIV-1 envelope) from which it was derived. Thus, N36Mut(e,g) and derivatives has potential as an anti-HIV therapeutic agent as a HIV fusion inhibitor.
Inventors:
Marius G. Clore (NIDDK) Carole A. Bewley (NIDDK) John M. Louis (NIDDK)
Patent Status:
DHHS Reference No. E-236-2002/0
Relevant Publication:
This research is described, in part, in CA Bewley et al., “Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41,” J. Biol. Chem. (2002 Apr 19) 277(16):14238-14245; Epub on 21 Feb 2002 as doi:10.1074/jbc.M201453200.
Licensing Status: This technology is no longer available for licensing.
For Additional Information Please Contact: Sally Hu PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5606
Email: hus@mail.nih.gov
Fax: (301) 402-0220
